Related Experiment Videos
[Effectiveness and the methods of using streptokinase in myocardial infarct and preinfarct stenocardia]
Insights
Streptokinase treatment significantly reduces complications and improves outcomes for myocardial infarction patients. Early administration within 6 hours and in younger patients enhances its effectiveness.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction (MI) poses significant mortality and morbidity risks.
- Limited treatment options historically existed for acute MI.
- Anticoagulants have a role, but their comparative effectiveness requires evaluation.
Purpose of the Study:
- To evaluate the effectiveness of streptokinase in treating myocardial infarction.
- To compare streptokinase treatment with a control group and anticoagulant therapy.
- To identify factors influencing streptokinase efficacy.
Main Methods:
- Comparative analysis of patient outcomes.
- Inclusion of a control group receiving no specific treatment.
- Administration of streptokinase to the treatment group.
- Comparison with patients receiving anticoagulant therapy.
Main Results:
- Lower incidence of recurrent myocardial infarctions in the streptokinase group.
- Reduced rates of congestive heart failure, shock, and thromboembolic complications.
- Improved disease course and prognosis for preinfarction angina patients.
Conclusions:
- Streptokinase is effective in reducing complications and improving prognosis in myocardial infarction.
- Optimal timing for streptokinase administration is within 3-6 hours of symptom onset.
- Efficacy is maintained in younger patients (<65 years) and with shorter, lower-dose regimens.
Abstract:
The effectiveness of streptokinase treatment of patients with myocardial infarction as compared to the control group and patients given anticoagulants is analysed. It is shown that the frequency of recurrent myocardial infarctions, congestive circulatory insufficiency, shock, and thromboembolic complications is lower in the group of patients treated with streptokinase than in the control group. Streptokinase improves the course of the disease and the prognosis in patients with preinfarction angina pectoris. The effect of streptokinase is higher in the first 3--6 hours after the development of myocardial infarction and in individuals under the age of 65. The effectiveness of the treatment does not diminish when the drug is injected for a short time and in small doses (300,000--750,000 U).